EU Spurns Gilead’s Aztreonam

3/20/09

Gilead Sciences, the Foster City, CA-based biotech company that has a research center in Seattle, said a scientific committee of the European Union adopted a negative opinion of its aztreonam lysine drug. The treatment, an inhalable antibiotic for cystic fibrosis developed by Seattle-based Corus Pharma, was turned down by the FDA last fall. EU regulators said Gilead needs more evidence about long-term benefits, repeated treatments in different age groups, and risk of bacterial resistance, said Thomas Russo, an analyst with Robert W. Baird.

By posting a comment, you agree to our terms and conditions.